Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu, Stephen A. Harrison, V. Loustaud‐Ratti, Christophe Bureau, Eric Lawitz, Manal F. Abdelmalek, Naim Alkhouri, Sven Francque, Hugo Girma, Raphaël Darteil, Harold Couchoux, Myles Wolf, Arun J. Sanyal, Jacky Vonderscher, Piétro Scalfaro
Topics & Concepts
TolerabilityPlaceboMedicineInternal medicineClinical endpointGastroenterologyUrologyRenal functionSteatohepatitisEndocrinologyFatty liverAdverse effectRandomized controlled trialPathologyAlternative medicineDiseaseLiver Disease Diagnosis and TreatmentDrug Transport and Resistance MechanismsLiver Diseases and Immunity